First Trust Advisors LP Sells 20,975 Shares of Glaukos Co. (NYSE:GKOS)

First Trust Advisors LP lowered its stake in Glaukos Co. (NYSE:GKOS - Free Report) by 25.9% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 59,874 shares of the medical instruments supplier's stock after selling 20,975 shares during the quarter. First Trust Advisors LP owned 0.11% of Glaukos worth $8,978,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. IFP Advisors Inc purchased a new stake in Glaukos during the 4th quarter valued at $43,000. Asset Planning Inc purchased a new stake in shares of Glaukos during the fourth quarter worth about $90,000. Picton Mahoney Asset Management bought a new stake in shares of Glaukos in the fourth quarter worth about $125,000. SBI Securities Co. Ltd. purchased a new position in Glaukos during the 4th quarter valued at about $153,000. Finally, Smartleaf Asset Management LLC raised its position in Glaukos by 275.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier's stock valued at $164,000 after purchasing an additional 807 shares during the last quarter. Hedge funds and other institutional investors own 99.04% of the company's stock.

Glaukos Stock Up 4.9 %

Shares of GKOS stock traded up $4.06 during mid-day trading on Friday, hitting $87.60. The company's stock had a trading volume of 2,188,300 shares, compared to its average volume of 673,086. The stock has a market cap of $5.00 billion, a price-to-earnings ratio of -30.52 and a beta of 0.88. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. Glaukos Co. has a 52-week low of $77.10 and a 52-week high of $163.71. The business has a 50-day moving average price of $97.60 and a 200 day moving average price of $128.81.

Glaukos (NYSE:GKOS - Get Free Report) last posted its earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.11. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The business had revenue of $106.66 million for the quarter, compared to analysts' expectations of $102.78 million. During the same quarter in the prior year, the business earned ($0.70) EPS. The business's revenue for the quarter was up 24.6% compared to the same quarter last year. Research analysts predict that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Insider Buying and Selling

In other Glaukos news, insider Tomas Navratil sold 3,416 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the sale, the insider now owns 72,437 shares in the company, valued at approximately $10,658,380.18. This represents a 4.50 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Alex R. Thurman sold 1,520 shares of the firm's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the sale, the chief financial officer now directly owns 53,431 shares in the company, valued at approximately $5,708,568.04. This represents a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

GKOS has been the topic of several research analyst reports. Wells Fargo & Company cut Glaukos from an "overweight" rating to an "equal weight" rating and reduced their target price for the company from $160.00 to $86.00 in a research note on Thursday. Mizuho decreased their price objective on shares of Glaukos from $200.00 to $175.00 and set an "outperform" rating for the company in a report on Wednesday, April 16th. Piper Sandler cut their target price on shares of Glaukos from $180.00 to $165.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 15th. Stifel Nicolaus reduced their price target on shares of Glaukos from $140.00 to $115.00 and set a "buy" rating on the stock in a research report on Thursday. Finally, Truist Financial restated a "buy" rating and issued a $135.00 price objective (down from $140.00) on shares of Glaukos in a report on Thursday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $137.62.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.